Xilio Therapeutics reports mixed Phase II results for vilastobart with Tecentriq in colorectal cancer. While showing promise in some subsets with a 27% ORR, efficacy in patients with liver metastases ...
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...
And if you’re not thinking data first too - prioritizing your data quality - you risk falling behind your competition and missing out on valuable opportunities.
Flagship Pioneering partners with CUHP and MTI to advance research, clinical translation, and talent development in the UK. The collaboration gives Flagship’s companies access to Cambridge’s resources ...
Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma.